ArticleNutrition & metabolism2025
Association between methylmalonic acid and composite dietary antioxidant index and diabetic retinopathy: data from National Health and Nutrition Examination Survey.
Article in Nutrition & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOxidative stress and mitochondrial dysfunction play an important role in diabetic retinopathy (DR), and serum methylmalonic acid (MMA) levels are related to oxidative stress and mitochondrial dysfunction. We aimed to explore the impact of MMA levels and the composite dietary antioxidant index (CDAI) on DR risk in patients with diabetes.
methodsData on patients with diabetes from the 1999-2004 and 2011-2014 National Health and Nutrition Examination Survey (NHANES) datasets were included in this cross-sectional study. Logistic regression analysis (accounting for NHANES survey weights) was used to explore the association of MMA (< 250, ≥ 250 nmol/L) and CDAI (>-0.5, ≤-0.5) with DR risk, and the association was reported as odds ratio (OR) and 95% confidence interval (CI). The combined effect of MMA and CDAI on DR risk was also explored.
resultsA total of 2,373 patients with diabetes were included and 547 (20.48%) patients had DR. MMA levels ≥ 250 nmol/L (OR = 1.47, 95%CI: 1.01-2.13) (vs. <250 nmol/L) were associated with higher odds of DR in patients with diabetes, whereas there was no significant difference in the effect of CDAI >-0.5 and CDAI ≤-0.5 on DR risk (P > 0.05). There was an interaction between MMA and CDAI that increased the risk of DR (OR = 2.24, 95%CI: 1.15-4.35; P
conclusionThere is an interaction between MMA and CDAI that increases the risk of DR, and CDAI plays a moderating role in this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.